Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1 6Phase NA 5Phase 3 5Phase 1/2 4Phase 4 2Phase 2/3 2

Status

Completed 23Terminated 20Active not recruiting 7Unknown 6Recruiting 6Withdrawn 2Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasm Metastasis 3Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Lymphoma 1Advanced Solid Tumor 1Advanced Gastric Cancer 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22Radiotherapy 19toripalimab 18pembrolizumab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Unknown × spartalizumab × Clear all
NCT04213404 2022-04-21

RISE-HN

National Taiwan University Hospital

Phase 1 Unknown
13 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04478461 2020-11-13

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1 Unknown
21 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03468751 2020-06-01

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Henlix, Inc

Phase 1 Unknown
30 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04072900 2020-04-28

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Xiangya Hospital of Central South University

Phase 1 Unknown
30 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT03393416 2019-08-29

A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

HRYZ Biotech Co.

Phase 1 Unknown
28 enrolled
Gastrointestinal

Advanced Gastric Cancer

NCT03991559 2019-08-28

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Chinese PLA General Hospital

Phase 1 Unknown
20 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡